ASCO 2023 | Remaining questions regarding the use of front-line CDK4/6 inhibitors in breast cancer

Gabe Sonke, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses remaining questions regarding the use of CDK4/6 inhibitors in breast cancer. In the ongoing Phase III SONIA trial, researchers are exploring several questions related to breast cancer treatment surrounding the search for biomarkers using liquid and tumor tissue samples. Another aspect under investigation is determining the preferred CDK4/6 inhibitor, although direct 1-to-1 comparisons are lacking. Lastly, the trial is examining whether aromatase inhibitors or fulvestrant, or even newer options, are the preferred endocrine partners in the treatment. These questions remain open for further investigation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.